Login to Your Account

ASCO 2013

Bergenbio's AXL-Kinase Inhibition Potential Is Broad

By Nuala Moran
Staff Writer

Wednesday, June 5, 2013
LONDON – Bergenbio AS has raised $6 million in a Series B round supported by all the existing investors, providing funding for a number of Phase I trials of its lead product BGB 324, a first-in-class AXL receptor tyrosine kinase inhibitor.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription